BRITISH COLUMBIA, Canada, Feb. 4 /CNW/ -- InNexus Biotechnology Inc. (OTC
Bulletin Board: IXSBF; TSX Venture: IXS.V; http://www.ixsbio.com), a drug
development company commercializing the next generation of monoclonal
antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces
Jeff Morhet, Chairman and CEO, will be presenting at the 11th Annual BIO CEO &
Investor Conference on Tuesday, February 10th at 10:30-10:55 AM ET in the Park
Ballroom at the Waldorf-Astoria in New York City.
Mr. Morhet will provide a brief corporate overview; discuss the company's
growth and how its antibody enhancement technology improves the potency of
existing and novel therapeutic products. Investors, venture capitalists,
company executives, scientists and other industry leaders will attend the
About BIO CEO
The 11th Annual BIO CEO & Investor Conference is the largest investor
conference focused on publicly traded biotech companies. The conference
provides a neutral forum where senior biotechnology executives, institutional
investors, industry analysts, venture capitalists, investment bankers and
other industry experts have the opportunity to shape the future investment
landscape of the biotechnology industry.
InNexus is a drug development company commercializing the next generation
of monoclonal antibodies based on its DXL technology, which improves the
potency of existing antibody products while opening new markets and disease
applications. DXL antibodies utilize unique, novel and patented methods and
technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own
in-house developmental facilities. These development resources provide
validation of protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and diagnostics. To
learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control, which may cause
actual results or performance to differ materially from those currently
anticipated in such statements.
For further information:
For further information: Wade Brooksby, Chief Financial Officer, InNexus
Biotechnology Inc., +1-480-862-7500 Web Site: http://www.ixsbio.com